The Food and Drug Administration said Friday it has approved meloxicam tablets for the treatment of osteoarthritis.
In comparisons between Vioxx and Celebrex, Merck would like to focus on the two drugs' labels.
Vioxx has an indication for treatment of acute pain; Celebrex does not _ it has been approved for the treatment of rheumatoid arthritis and osteoarthritis.
Two out of five Americans with chronic joint symptoms haven't sought a doctor's diagnosis, according to research by the Centers for Disease Control and Prevention.
And even among those diagnosed with arthritis, nearly three out of five are not undergoing treatment for it.
Like Celebrex, Merck is looking to get approval for Vioxx to treat osteoarthritis, which affects more than 16 million Americans.
But instead of also seeking indication for rheumatoid arthritis, which affects about 2 million Americans, it wants the FDA to approve Vioxx for acute pain treatment -- a market of more than 40 million Americans.
Celebrex, manufactured by St. Louis-based Monsanto Co.'s G.D.
Searle & Co. subsidiary, went on the market in January to treat osteoarthritis and rheumatoid arthritis.
Mayo Clinic site on nontraditional treatment: http://www.mayohealth.org/mayo/0002/htm/nontraditional.htm ``The scientific games have begun,'' declared Dr. David Eisenberg, director of the Center for Alternative Medicine Research and Education at Beth Israel Deaconness Medical Center in Boston.
Or, as Dr. Barrie Cassileth, chief of integrative medicine at Memorial Sloan-Kettering Cancer Center in Manhattan, said: ``The research is just coming into its maturity.
It's bar mitzvah time.'' Among the most common types of arthritis:
